Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell Treatment: Evidence From Randomized Controlled Trial Data on Tisagenlecleucel for Diffuse Large B-Cell Lymphoma.

Chen, Alice J; Zhang, Jie; Agarwal, Abhijit; Lakdawalla, Darius N

Chen, Alice J; Zhang, Jie; Agarwal, Abhijit; Lakdawalla, Darius N.

Afiliación

Chen AJ; Sol Price School of Public Policy and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA. Electronic address: alicejc@price.usc.edu.
Zhang J; Novartis Pharmaceuticals, Basel, Switzerland.
Agarwal A; Novartis Pharmaceuticals, Basel, Switzerland.
Lakdawalla DN; Sol Price School of Public Policy and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.

Value Health ; 25(8): 1344-1351, 2022 08.

Article en En | MEDLINE | ID: mdl-35341689

Asunto(s)

Linfoma de Células B Grandes Difuso; Receptores Quiméricos de Antígenos; Humanos; Lactato Deshidrogenasas; Linfoma de Células B Grandes Difuso/tratamiento farmacológico; Recurrencia Local de Neoplasia; Receptores de Antígenos de Linfocitos T; Receptores Quiméricos de Antígenos/uso terapéutico; Linfocitos T/patología; Listas de Espera

Palabras clave

access; chimeric antigen receptor T-cell therapies; survival gains; treatment efficacy; wait time

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Receptores Quiméricos de Antígenos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Value Health Asunto de la revista: FARMACOLOGIA Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google